The first United States Food and Drug Administration(FDA) approved CAR-T cell treatment, in August 2017, is tisagenlecleucel. It is indicated in patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in the second or later relapse. It also has indications in adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma. The second U.S. FDA approved CAR-T cell treatment, in October 2017, is axicabtagene ciloleucel which is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Of note, neither treatment has an indication for patients with primary central nervous system(CNS) lymphoma. According to U.S. National Institute of Health clinical trial registration, multiple clinical trials are currently going on with CAR-T cell treatment for different malignancies including multiple myeloma, CNS tumor, hepatocellular carcinoma, lung cancer, etc.